Treatment of neurological deficits in the striatum or substanta nigra pars compacta
OwnerDarin Messina, Sanjay Mistryinventors
Life of this patent
Estimating the term…
Abstract
The present invention is directed to methods of treating neurological deficits resulting from injury or disease to the striatum or substanta nigra pars compacta of a human by administering BMP7 to the striatum or substanta nigra pars compacta of a human in amounts effective to induce cell populations having the capacity to differentiate towards a dopaminergic phenotype to in fact differentiate towards a dopaminergic phenotype, and to neurotrophic compositions and matrices suitable for use in such treatments.
Claims13
A method of treating neurological deficits resulting from injury or disease to the striatum or substanta nigra pars compacta of a human comprising administering BMP7 to said striatum or said substanta nigra pars compacta of said human in amounts effective to induce cell populations comprising the capacity to differentiate towards a dopaminergic phenotype to in fact differentiate towards said dopaminergic phenotype.
A neutrophic composition suitable for treating neurological deficits resulting from injury or disease to the striatum or substanta nigra pars compacta of a human, comprising:
- BMP7in amounts effective to induce cell populations comprising the capacity to differentiate towards a dopaminergic phenotype to in fact differentiate towards said dopaminergic phenotype,
- Sonic Hedgehog;
- FGF8;
- and
- a physiologically acceptable carrier.
Dependencies are inferred from the claim text.